ATE253352T1 - Verwendung einer zusammensetzung enthaltend polyether block copolymere - Google Patents

Verwendung einer zusammensetzung enthaltend polyether block copolymere

Info

Publication number
ATE253352T1
ATE253352T1 AT96925056T AT96925056T ATE253352T1 AT E253352 T1 ATE253352 T1 AT E253352T1 AT 96925056 T AT96925056 T AT 96925056T AT 96925056 T AT96925056 T AT 96925056T AT E253352 T1 ATE253352 T1 AT E253352T1
Authority
AT
Austria
Prior art keywords
polyether block
composition containing
block copolymers
containing polyether
compositions
Prior art date
Application number
AT96925056T
Other languages
English (en)
Inventor
Alexander V Kabanov
Valery Yu Alakhov
Peter G Sveshnikov
Eugenii S Severin
Original Assignee
Supratek Pharma Inc
Alexander V Kabanov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc, Alexander V Kabanov filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE253352T1 publication Critical patent/ATE253352T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT96925056T 1995-06-07 1996-06-07 Verwendung einer zusammensetzung enthaltend polyether block copolymere ATE253352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,978 US5817321A (en) 1992-10-08 1995-06-07 Biological agent compositions
PCT/IB1996/000799 WO1996040055A2 (en) 1995-06-07 1996-06-07 Biological agent compositions

Publications (1)

Publication Number Publication Date
ATE253352T1 true ATE253352T1 (de) 2003-11-15

Family

ID=23902177

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925056T ATE253352T1 (de) 1995-06-07 1996-06-07 Verwendung einer zusammensetzung enthaltend polyether block copolymere

Country Status (12)

Country Link
US (1) US5817321A (de)
EP (2) EP0871432B1 (de)
JP (1) JP4167299B2 (de)
CN (1) CN1192678A (de)
AT (1) ATE253352T1 (de)
AU (1) AU700021B2 (de)
BR (1) BR9609176A (de)
CA (1) CA2222776A1 (de)
DE (1) DE69630615T2 (de)
NZ (1) NZ313271A (de)
RU (1) RU2166934C2 (de)
WO (1) WO1996040055A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
EP0832653A1 (de) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
US6649702B1 (en) * 1999-05-19 2003-11-18 University Of Utah Research Foundation Stabilization and acoustic activation of polymeric micelles for drug delivery
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
ATE304870T1 (de) * 1999-10-29 2005-10-15 Los Angeles Childrens Hospital Verfahren und material zur hämostase bei knochen
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
ATE311358T1 (de) 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
GB0120701D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Pharmaceutical formulations
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
PL211116B1 (pl) * 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
HU0104790D0 (en) * 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
EP1465618A2 (de) * 2001-12-20 2004-10-13 Bristol-Myers Squibb Company Pharmazeutische zusammensetzungen oral aktiver taxanderivate mit verbesserter bioverfügbarkeit
RU2201230C1 (ru) * 2001-12-24 2003-03-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство флузол, обладающее противогрибковым действием
WO2003066049A1 (en) * 2002-02-06 2003-08-14 Combinatorx, Incorporated Combinations for the treatment of fungal infections
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534238A1 (de) * 2002-07-29 2005-06-01 ALZA Corporation Formulierungen und dosierformen fuer die kontrollierte abgabe von topiramat
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
RU2226092C1 (ru) * 2002-11-29 2004-03-27 Пятигорская государственная фармацевтическая академия Противотуберкулезные ректальные суппозитории
TWI367113B (en) * 2003-02-12 2012-07-01 Syncera Inc Random and non-random alkylene oxide polymer alloy compositions
AU2004222439B2 (en) * 2003-03-20 2008-08-21 Nanocarrier Kabushiki Kaisha Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2007501248A (ja) * 2003-08-06 2007-01-25 アルザ・コーポレーシヨン 増進した分散調合物による長時間にわたるトピラメートの均一送達
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
RU2248205C1 (ru) * 2003-09-18 2005-03-20 Открытое акционерное общество "Щелковский витаминный завод" Лекарственное средство в виде желатиновой капсулы
US20050112204A1 (en) * 2003-11-25 2005-05-26 Pfizer Inc. Pharmaceutical formulations
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
AU2004312082A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
US20090214657A1 (en) * 2005-11-30 2009-08-27 Muhammad Waseem Tahir Qazi Orally Absorbed Pharmaceutical Formulation and Method of Administration
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
RU2008132841A (ru) * 2006-01-10 2010-02-20 ИННОВАФОРМ ТЕКНОЛОДЖИЗ, ЭлЭлСи (US) Система доставки пестицидов
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
ZA200808329B (en) * 2006-04-24 2010-05-26 Bruce Medical Ab Polymer-based anti-cancer agents
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2652656A1 (en) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
BRPI0603871B8 (pt) * 2006-08-24 2021-05-25 Univ Brasilia Fundacao composições farmacêuticas para o tratamento de tripanossomíases e de doença de chagas
KR20100045508A (ko) * 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
WO2009114368A2 (en) 2008-03-07 2009-09-17 University Of Utah Research Foundation Activated nitric oxide donors and methods of making and using thereof
WO2009117333A1 (en) * 2008-03-17 2009-09-24 University Of Utah Research Foundation Dithiocarbamate metal chelates and methods of making and using thereof
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
US8445271B2 (en) * 2010-05-03 2013-05-21 Enzo Life Sciences, Inc. Processes and kits for determining multi-drug resistance of cells
RU2501570C1 (ru) * 2012-05-11 2013-12-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) федеральный университет" (ФГАОУВПО КФУ) Трехфункциональные блоксополимеры этиленоксида и пропиленоксида для доставки активных веществ в живые клетки
US10792331B2 (en) * 2015-09-09 2020-10-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
CN109324512A (zh) * 2018-12-05 2019-02-12 华北电力大学 一种利用已知模型信息整定降阶自抗扰控制器参数的方法
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
WO1994008564A1 (en) * 1992-10-08 1994-04-28 Valery Yu Alakhov Composition of antineoplastic agents incorporated in micelles

Also Published As

Publication number Publication date
WO1996040055A3 (en) 1997-04-24
EP1310244A2 (de) 2003-05-14
JPH11507619A (ja) 1999-07-06
WO1996040055A2 (en) 1996-12-19
CA2222776A1 (en) 1996-12-19
DE69630615T2 (de) 2004-09-30
BR9609176A (pt) 1999-08-24
JP4167299B2 (ja) 2008-10-15
EP0871432B1 (de) 2003-11-05
AU6529796A (en) 1996-12-30
EP0871432A2 (de) 1998-10-21
EP1310244A3 (de) 2004-01-14
CN1192678A (zh) 1998-09-09
DE69630615D1 (de) 2003-12-11
AU700021B2 (en) 1998-12-17
NZ313271A (en) 2001-03-30
US5817321A (en) 1998-10-06
RU2166934C2 (ru) 2001-05-20

Similar Documents

Publication Publication Date Title
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
DE69617042D1 (de) Fluorhaltige, elastische copolymere, härtbare zusammensetzung und daraus hergestellte dichtungsmasse
DE3583560D1 (de) Polymerisationsverfahren und polymerzusammensetzungen.
DE68920529D1 (de) Blockcopolymere und Zusammensetzungen davon.
JPS6445433A (en) Polyarylenesulfide block copolymer, manufacture and use
DE69007344D1 (de) Blockcopolymerzusammensetzung.
EP0575123A3 (de) Acethylencopolymerzusammensetzung.
AU1156688A (en) Wettable, hydrophilic, soft and oxygen permeable copolymer compositions
BR8902244A (pt) Composicao de revestimento aquosa,auto-reticulavel e polimero de vinila
FI965203A0 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
DE69113810D1 (de) (poly)sulfid enthaltende polycitraconimide und polyitaconimide.
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
DE59008276D1 (de) Hydrophile, quellfähige Pfropfcopolymerisate, deren Herstellung und Verwendung.
EP0767185A4 (de) Acrylatcopolymer und solches enthaltende polymerzusammensetzung
IL209189A0 (en) Copolymer 1 related polypeptides and their use as molecular weight markers
DE3853340D1 (de) Dien-Blockpolymer und Polymerzusammensetzung.
DE3680737D1 (de) Poly(etherimid-carbonat)-blockcopolymere und diese enthaltende polymermischungen.
DE69433657D1 (de) Ethylen-Alpha-Olefin Copolymere und daraus hergestellte Formteile
DE69602178D1 (de) 2-oxo-1,3-dioxolangruppen enthaltende copolymere und daraus hergestellte beschichtungen
DE3850062D1 (de) Fluorierte Polymere und Copolymere enthaltende Perfluorpolyätherblöcke.
DE59006687D1 (de) Dispersionen von Perfluoralkylgruppen enthaltenden Copolymerisaten.
GR3019058T3 (en) 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
DE3587486D1 (de) Imidazolinone enthaltende polymere und copolymere.
DE69428350D1 (en) Polymere ionene als anthelminthika in tieren
DE3766276D1 (de) Gegen abblaettern bestaendige polymerzusammensetzung, sowie beschichtung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties